MetasTx
Business Services · Pennsylvania, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
100 S Jackson Ave, Pittsburgh, Pennsylva...Website
www.metastx.comRevenue
<$5 MillionIndustry
About MetasTx
MetasTx Org Chart
Is MetasTx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Click to see if MetasTx had a recent Job posting/layoffs
Earning: See what the market has to say on MetasTx recently announced quarterly report
MetasTx, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once MetasTx has new funding data
Product Launch: Get notified when MetasTx launches new products
Check if MetasTx has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at MetasTx
Check out if MetasTx is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined MetasTx as Masked Content
Find 2 more new buyers
Compare Similar Companies to MetasTx
Compare insights from companies similar to MetasTx, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
MetasTx is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
MetasTx is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about MetasTx.
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding MetasTx
MetasTx is a precision oncology platform focused on developing novel therapeutics to prevent cancer metastasis, particularly in high-risk prostate cancer patients. The company combines a unique companion diagnostic, funded by the National Cancer Institute, with next-generation KIT inhibitors to identify and treat patients at risk of metastasis effe... Read More